Citius Pharmaceuticals is trading at $0.49 (-5.28%) after sliding from its prior close near $0.52, with no new company-specific announcements to explain the move.
- The decline is consistent with broader risk-off pressure in small-cap biotech and a weak tape for growth names, as the Nasdaq Composite is down 1.15%.
- Sentiment may also be weighed down by a recent July 2026 financing and dilution backdrop.